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Abstract. Purpose: It is generally assumed that the
biodistribution and pharmacokinetics of radiolabelled an-
tibodies remain similar between dosimetric and therapeu-
tic injections in radioimmunotherapy. However, circulation
half-lives of unlabelled rituximab have been reported to
increase progressively after the weekly injections of stan-
dard therapy doses. The aim of this studywas to evaluate the
evolution of the pharmacokinetics of repeated 131I-ritux-
imab injections during treatment with unlabelled rituximab
in patients with non-Hodgkin’s lymphoma (NHL).
Methods: Patients received standard weekly therapy with
rituximab (375 mg/m2) for 4 weeks and a fifth injection at
7 or 8 weeks. Each patient had three additional injections
of 185 MBq 131I-rituximab in either treatment weeks 1, 3
and 7 (two patients) or weeks 2, 4 and 8 (two patients).
The 12 radiolabelled antibody injections were followed
by three whole-body (WB) scintigraphic studies during 1
week and blood sampling on the same occasions. Addi-
tional WB scans were performed after 2 and 4 weeks post
131I-rituximab injection prior to the second and third injec-
tions, respectively.
Results: A single exponential radioactivity decrease for
WB, liver, spleen, kidneys and heart was observed. Biodis-
tribution and half-lives were patient specific, and without
significant change after the second or third injection com-
pared with the first one. Blood T1/2β, calculated from
the sequential blood samples and fitted to a bi-exponential
curve, was similar to the T1/2 of heart and liver but shorter
than that of WB and kidneys. Effective radiation dose cal-
culated from attenuation-corrected WB scans and blood
using Mirdose3.1 was 0.53+0.05 mSv/MBq (range 0.48–
0.59 mSv/MBq). Radiation dose was highest for spleen and
kidneys, followed by heart and liver.
Conclusion: These results show that the biodistribution and
tissue kinetics of 131I-rituximab, while specific to each pa-
tient, remained constant during unlabelled antibody therapy.
RIT radiation doses can therefore be reliably extrapolated
from a preceding dosimetry study.
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Biodistribution – Pharmacokinetics
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Introduction
The unlabelled chimeric monoclonal antibody (MAb)
rituximab (Mabthera) and two radiolabelled mouse MAbs,
ibritumomab tiuxetan (Zevalin) and tositumomab (Bexxar),
all directed against the CD20 antigen, have been approved
for the treatment of non-Hodgkin’s lymphoma (NHL). Ra-
dioimmunotherapy (RIT) with Zevalin [1, 2] uses 90Y-la-
belledmouseMAb 2B8, combinedwith two administrations
of 250 mg/m2 unlabelled chimeric MAb C2B8 (rituximab).
Bexxar treatment [3–5] is based on injection of 131I-labelled
mouse MAb anti-B1 combined with two administrations of
450 mg per patient of the same unlabelled MAb.
The number of reports on RIT of lymphoma is rapidly
increasing [6–8]. Besides the approved radiopharmaceu-
ticals, 131I-rituximab has been used in low- and high-dose
RIT [9–11]. First in vitro and in vivo alpha-radiation ther-
apy experiments usingDTPA-rituximab, labelledwith 213Bi
and 149Tb, have also been reported [12, 13].
Both approved RITs are based on the injection of a sin-
gle therapeutic dose of radiolabelled mouse MAb that may
be preceded by the injection of a dosimetric dose of MAb,
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labelled with 111In in the case of Zevalin and with 131I in
that of Bexxar. In heavily pretreated patients, the appear-
ance of human anti-mouse IgG antibodies (HAMA) has
been observed in 17% after treatment with Bexxar antibody
[4] and in a lower percentage (2%) after therapywith Zevalin
[2]. However, upfront treatments of chemotherapy-naïve
patients or repeated treatment cycles with mouse monoclo-
nal antibodies might be more immunogenic. In contrast,
after standard rituximab treatment with four weekly in-
jections in patients having had previous chemotherapies,
human anti-chimeric IgG antibodies (HACA) have been
observed in less than 1%.
Dosimetry evaluation of RIT is frequently performed in
a dosimetry study preceding the RIT, since it cannot be
performed directly under therapy conditions because the
gamma-radiation is either too high in the case of 131I-la-
belling or absent in the case of 90Y-labelling. However,
it has been reported that the blood half-life of unlabelled
rituximab progressively increases after the successive in-
jections during therapy [14, 15]. The reason for the pro-
longation of the blood half-life of unlabelled rituximab has
not been entirely elucidated, though saturation of the easily
accessible antigenic sites may be partially responsible.
Dosimetric data obtained during a first administration of
rituximab may be unable to predict the radiation exposure
of the patient in a subsequent RIT performed 1–2 weeks
later if half-life prolongation also occurs for the radiola-
belled antibody. This is even more important when intend-
ing to administer multiple RIT courses in order to increase
the total administered activity while limiting toxicity.
With the intention of delivering repeated courses of RIT
with radiolabelled rituximab, in this study we investigated
the biodistribution and kinetics of 131I-rituximab after re-
peated injections during standard rituximab therapy in pa-
tients with lymphoma. Repeated injections of diagnostic
doses of 131I-rituximab were performed in weeks 1, 3 and 7
or 2, 4 and 8, respectively. All injections were followed by
standardised, sequential anterior and posterior whole-body
(WB) scintigraphic studies and blood sampling.
Materials and methods
Patients
Evolution of the biokinetics of repeated radiolabelled antibody injec-
tions was studied in four patients (one female and three males), aged
60.8±12.2 years, with relapsed NHL after having obtained written
informed consent. Patient characteristics and their lymphoma history
are shown in Table 1. Inclusion criteria included adequate renal and
hepatic functions (aspartate aminotransferase, bilirubin and creati-
nine were not to exceed twice the upper normal limit, i.e. <100 U/l,
<42 μmol/l and <212 μmol/l, respectively) and a negative HAMA
test. The study protocol had been approved by the local Ethics Com-
mittee and the Swiss authorities (Swissmedic and the Federal Office
of Public Health, Section of Radioprotection).
Antibody radiolabelling
The 12 radiolabellings were performed adopting the rules of good
clinical practice (GCP) as described [16]. Briefly: 0.2ml clinical grade
rituximab (2 mg) solution, provided by Roche Pharma (Reinach,
Switzerland), and 100μl freshly prepared chloramineTsolution (50μg
per 0.1 ml 0.15 M sterile phosphate buffer pH 7) were added to
370 MBq Na131I solution (no-carrier-added Na131I in phosphate
buffer, MDS Nordion S.A., Fleurus, Belgium), previously diluted to
200 μl with 0.15 M phosphate buffer pH 7.0. After 5 min at room
temperature, labelling efficacy was controlled by thin-layer chroma-
tography (ITLC, methanol/0.9% saline=85/15) and the labelling
solution pumped at 0.5 ml/min flow through a Dowex resin filter
column [1.8 g anion exchange resin (Dowex 1×8–100) in a 2-ml
reversible tube (Supelco, Buchs, Switzerland) in sterile 0.9% NaCl
solution] into a new vial. The purified radiolabelled antibody solution
was sterile filtered (MILLEX-GV 0.22-μm millipore filters, Milli-
pore Corp., Bedford, MA, USA) into a sterile penicillin vial for clin-
ical use. Sterility was demonstrated for three sequential assays before
radiolabellings were performed for injection of patients. Foreseeing
use of this radiolabelling procedure for therapy, a semi-automatic set-
up was chosen for antibody labelling and purification [16].
Chemicals and solvents were fromMerck (Dietikon/ZH, Switzer-
land) and Fluka (Buchs, Switzerland). Analytical size-exclusion high-
performance liquid chromatography (HPLC) was performed on a
guard-protected TSK-Gel column: TSK 3000 SW 300 mm×7 mm
(Toyo SodaManufacturing Co., Yamaguchi, Japan). Thin-layer chro-
matograms (Pall Corp., AnnArbor, USA)were scanned on a Berthold
LB 284 linear analyser.
Table 1. Patient characteristics
Patient Sex Age
(years)
Lymphoma type Pre-treatment history
1a Female 58 Diffuse large B-cell lymphoma Three chemotherapies including intensification,
rituximab, radiotherapy (2 years’ evolution)b
2 Male 45 Follicular lymphoma Radiotherapy, four chemotherapies including
intensification (10 years’ evolution)
3 Male 67 Diffuse large B-cell lymphoma Radiotherapy, two chemotherapies(2 years’ evolution)
4 Male 73 Anaplastic diffuse large B-cell lymphoma Two chemotherapies (10 years’ evolution)
aPatients 1 and 4 had 131I-rituximab injection at Mabthera treatment weeks 1, 3 and 7 and patients 2 and 3 at weeks 2, 4 and 8
bPatient 1 also suffered from an invasive breast cancer, treated with radiotherapy before inclusion in this study
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Binding assay
Immunoreactivity of the 12 freshly radiolabelled antibody prepa-
rations was measured without delay in duplicates on Daudi lym-
rewerephoma B cells in the exponential growth phase using five
sequential dilutions betweenone and10×106 cells.Daudi cells (Amer-
ican Type Culture Collection ATCC) are well known for surface
expression of the CD20 antigen. Cells were cultured in RPMI 1640
medium+Glutamax I, containing 10% foetal calf serum, penicillin
and streptomycin. First results of a Scatchard determination indicated
the presence of 9.2×104 antibody binding sites per cell and an affinity
Ka of
131I-rituximab of 3.0×108 l/M, well compatible with the re-
ported affinity of 125I-rituximab [17], suggesting that the immuno-
reactivity had been preserved.
For binding determination, 6 ng (1 kBq) of 131I-rituximab was
incubated at 37°C for 2 h with Daudi cells in a volume of 200 μl PBS
(0.15 M NaCl and 0.01 M phosphate buffer pH 7) containing 2%
foetal calf serum. After two washings, cell-bound radioactivity was
counted in comparison to a 100% standard sample and expressed
in % of total input activity. Non-specific binding (generally <3%)
was assessed by competition with 100 μg unlabelled antibody and
subtracted for determination of specific binding. Specific binding
results were expressed as maximal observed binding on 107 fresh
Daudi cells and using extrapolation to infinite antigen excess accor-
ding to Lindmo et al. [18].
Patient injection and data collection
Patients had standard weekly therapy with rituximab for 4 weeks and
a fifth injection at 7 or 8 weeks. The standard therapy doses of un-
labelled rituximab (375 mg/m2) were infused over 2–3 h. Each of
the four patients had three additional injections of fresh radiolabelled
131I-rituximab in either treatment weeks 1, 3 and 7 (two patients) or
weeks 2, 4 and 8 (two patients). 131I-rituximab (185 MBq) injections
were performed over 30min immediately after injection of unlabelled
antibody, except for the first radiolabelled antibody injection in pa-
tients 1 and 4, where the 131I-rituximab was scheduled 24 h after the
first administration of unlabelled rituximab. This procedure takes into
account the higher incidence of adverse reactions observed during the
first rituximab infusion. Standard precautions were used during in-
jection, including frequent control of vital parameters. Patients were
scanned with a large field of view dual-head BIAD camera (Trionix,
Twinsburg, Ohio) equippedwith high-energy parallel collimators and
using amatrix of 1,024×256. Camera uniformity, background and the
energy peaks were checked daily.
Scanning procedure was performed as described by Wahl et al.
[19]: Prior to all patient scans, one scan of background activity and
another scan of a stored 131I standard sample (a standard of ∼8 MBq
was prepared at day 0, in 10 ml solution) were recorded using a scan
speed of 10 cm/min, a scan length of 200 cm and an energy peak of
364 keVwith a window of 28%, using predefined positions of camera
heads, table and standard sample. The patient was then scanned under
identical conditions, on day 0 immediately after antibody perfusion
(without bladder voiding, 100% reference scan), on day 2, 3 or 4 and
on day 6 or 7 (after bladder voiding). In patients 1, 2 and 3, additional
scintigraphic studies were performed just before the perfusion of the
second and third radiolabelled antibody injections.
The standard sample scans and the patient WB scans were cor-
rected for background activity, measured on the same day. The back-
ground corrected activities of day 2, 3 or 4 and day 6 or 7 were
expressed in % of activity measured on day 0. Regions of interest
(ROIs) of organs were determined, and geometric means of anterior
and posterior scintigraphic studies used for half-life and dosimetry
determinations.
Blood samples were obtained before each radiolabelled antibody
injection and at 15 min (100% reference) and 2 h post injection
as well as at the time of the second and third WB scans. A stan-
dard of injected activity allowed back-calculation of total blood vol-
ume distribution of the injected radiolabelled antibody. Blood and
plasma radioactivity was determined in a gamma counter (Wizard,
PerkinElmer, Wallac OY, Turku, Finland) together with the standard
radioactivity sample.
Tissue and blood radioactivity kinetics
WBand tissue activities of the first 6–7 days post injection were fitted
to a single exponential curve, since no reproducible deviation from
that curve was observed.
Blood half-lives α and β were determined by fitting measured
activity data to a bi-exponential curve according to the formula:
Activity tð Þ ¼ A1  e1t þ A2  e2t
where A1 is the fractional activity exhibiting half-life α=ln 2/λ1 and
A2 is the fractional activity exhibiting half-life β=ln 2/λ2.
Dosimetry
Dosimetry was performed usingMirdose3.1 [20] based on the data of
the 12 injections from the four patients. Residence times for WB,
liver, kidneys, spleen and heart were calculated from the ROIs based
on geometric means of anterior and posterior scintigraphic studies
and using single exponential decrease of activity. Activity was cor-
rected for attenuation with an attenuation factor of 0.12 cm−1, using,
where available, organ and body sizes measured by CTand otherwise
standard organ sizes and a body thickness of 21 cm. Bone marrow
(BM) residence timewas calculated from blood activity according the
formula proposed [21]:
trm ¼ tblood mrm=mbloodð Þ 0:19= 1 hematocritð Þð Þ
where t is the residence time of blood and marrow, respectively, rm is
red marrow and m is the mass of blood or red marrow, respectively.
Red marrow mass was set at 1,120 and 1,050 g, respectively, for the
standard human phantoms of 70 and 57 kg [20]. Residence times of
the four organs, red marrow and rest of the body were then used for
calculation of radiation doses with Mirdose3.1 [20], using the
phantom closest to the patient effective weight. Mirdose results were
then extrapolated to effective patient weight using mathematical
inverse proportions of weight and dose.
HAMA assay
In the absence of a commercially available HACA assay, a HAMA
assay (HAMAElisa, Medac, Hamburg, Germany) was performed for
all four patients and was always negative. The HAMA assay was
repeated at 3 and 6 months after the first injection of the radiolabelled
Mab. Though not entirely covering the potential occurrence of
HACA, the HAMA assay may detect anti-HACA antibodies in many
patients since they can be directed against the mouse IgG framework
of the variable domains.
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Statistical analysis
Statistical comparisons were first performed using Student’s t test.
The multigroup comparisons were then performed with the ANOVA
analysis of variance to determine the potential prevalence of sig-
nificant subgroup differences. In the case of significant differences
between subgroups, these were sorted out by the subsequent Tukey
test.
Results
131I-labelling of rituximab and immunoreactivity
The 12 radiolabelled antibody fractions were prepared us-
ing 131I within 2 days of calibration. The radiochemical
yield of 131I-rituximab was 91.7±4.2%. The radiochemi-
cal purity after anion exchange chromatography of 131I-
rituximab, assessed by TLC (n=12), was 99.1±0.5%. These
results were confirmed using size-exclusion HPLC (n=5),
which showed a radiochemical purity of 131I-rituximab of
98.9±0.9% and 0.6±0.5% of aggregates, not significantly
different from the results for unlabelled precursor antibody.
Storage at 4°C for up to 8 h post labelling revealed the
absence of any further aggregation or degradation products;
antibody injections were performed within 2 h from prep-
aration. Upon longer storage for 24 h at 4°C, formation of
maximally 3% aggregateswas observed (results not shown).
Immunoreactivity of the preparations (n=12) was deter-
mined immediately after labelling by incubation with fresh
cultured Daudi cells in exponential growth phase. Mean
specific binding as measured on 107 cells was 48.3±9.0%.
Using extrapolation to infinite antigen excess according to
Lindmo et al. [18], a mean immunoreactivity of 72.2±
15.2% was calculated (Fig. 1). First results of an affinity
determination according to Scatchard linearisation [22] in-
dicated a Ka of 3.0×10
8 l/M, similar to the reported affinity
of 1.9×108 l/M for 125I-labelled rituximab [17].
Camera controls
Camera quality controls included a test of uniformity and
two scans performed under identical conditions as defined
for patient WB scans (scan length of 2 meter, identical po-
sition of camera heads and bed), once with a standard ac-
tivity sample of 8 MBq 131I (prepared at day 0 and re-used
for subsequent scans) and once for background determina-
tion. Camera measurement in the calibration setting and af-
ter background subtraction at day 0 gave 6.04±0.14×103
counts/MBq (n=12). Setting the initial measurements at
day 0 as 100%, subsequent calibration measurements be-
tween days 2 and 7were at 99.3±1.6% (range 96.4–103.4%,
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Fig. 1. Specific binding results (duplicates, non-specific binding has
been subtracted) are shown in a as obtained by incubation with five
dilutions of Daudi cells. The same results are shown in b in double
inverse plot according to Lindmo et al. [18], allowing extrapolation of
themaximal binding that would be obtained at infinite antigen excess.
While in a the maximal observed binding was 50.6%, in b the
intercept with the ordinate of the linear regression straight line,
defined as y=0.719x+0.0124 (r2=0.99), gives the reciprocal result of
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Fig. 2. Gamma camera quality control. On the days of patient
scanning, two control scans were performed, one with a 131I standard
sample prepared at day 0, and one of background, using identical
parameters as defined for patient WB scans. Taking the background-
subtracted scanning results of the 131I standard sample at day 0 as
100%, subsequent results were expressed in % of initial activity and
plotted against hours post initial calibration. The thin line shows the
theoretical exponential decrease in 131I activity. Note that the ob-
served results were all in between 96.4% and 103.4% of the expected
result
946
European Journal of Nuclear Medicine and Molecular Imaging Vol. 32, No. 8, August 2005
WB and tissue kinetics
The 12 radiolabelled antibody injections were well toler-
ated. After each injection, WB and tissue distributions and
biokinetics were determined using three WB scintigraphic
studies performed over 1 week. WB activity decrease was
determined using geometric means of anterior and posterior
WB scans including background and attenuation correc-
tion. This determination gave a mean T1/2 of 92.0±7.7 h
(range 81.5–99.0 h, Fig. 3, Table 2). When the half-lives
after each injection were analysed, a small intra-patient co-
efficient of variation (CV) was observed (mean CV=5.9%).
Using background-corrected anterior WB scans as re-
ported previously [19],WB radioactivitymeasurements also
showed a single exponential decrease (results not shown).
The average T1/2 was 92.9±9.2 h (range 80.7–103.0 h for
individual patients), very similar to the results derived from
the anterior and posterior scans. Intra-patient variation in
WB T1/2 after the three injections was small in this analysis,
too, with a CV ranging from 2.9% to 4.7%.
Tissue radioactivity of liver, spleen, kidneys and heart
followed a single exponential decrease (Fig. 3). In indi-
vidual patients, no major change and in particular no sys-
tematic prolongation of the effective tissue T1/2 appeared to
occur after the repeated applications of 131I-rituximab.
Blood radioactivity showed a bi-exponential decrease
that was calculated on the combined results of the three in-
jections per patient (Fig. 4), since in individual patients
activity of the samples after the three injections showed
only small deviations from the mean calculated value. Ef-
fective T1/2α was short (mean=6.0±2.4 h, range 4.1–9.4 h),
similar to the T1/2α observed for other radiolabelled an-
tibodies. The fraction of activity A1 with T1/2α was 39. 2%
(range 33.6–44.1%) as compared with the total activity.
While the effective T1/2β of blood was rather long (range































Fig. 3. WB (+), liver (◊), heart
(x), kidney (○) and spleen (Δ)
results are shown as obtained
from the four patients and the
three injections in each based
on anterior and posterior geo-
metric means corrected for
attenuation. a, b, c and d
represent data from patients 1,
2, 3 and 4, respectively. Only
mean single exponential de-
creases per patient are shown,
each fitted to the nine scan
results available per patient.
The corresponding half-lives
calculated for the three indi-
vidual injections per patient are
given in Table 3
Table 2. Average effective tissue half-lives (h) are shown as calculated from attenuation-corrected WB scans from the first 6–7 days post
injection in comparison with the mean blood effective T1/2β
Patient WB Heart Blood Liver Spleen Kidneys
1 99.0 84.5a 82.2a 84.5a 101.9b 99.0
2 81.5 62.4 66.9 66.6 72.2 83.5
3 96.3 72.2 73.3 73.7 93.7 101.9
4 91.2 57.3 64.6 73.0 70.7 92.4
Mean±1 SD 92.0±7.7 69.1±12.0 71.8±7.9 74.5±7.4 84.6±15.6 94.2±8.2
aThe half-lives for heart, liver and blood are strikingly similar in the four patients and different from those for WB and kidneys. ANOVA
followed by the Tukey test demonstrated a significant difference for the heart compared with kidneys (confidence value >95%), while the
other mentioned differences showed a tendency towards significance
bSpleen activity is variable compared with the other tissues, possibly indicating variable binding of the antibody to CD20-expressing cells
European Journal of Nuclear Medicine and Molecular Imaging Vol. 32, No. 8, August 2005
947
half-lives. Similar observations to those in blood weremade
in plasma (results not shown).
Average effective tissue T1/2 and blood T1/2β of indi-
vidual patients (Table 2) suggested the presence of two
groups of results, one including WB and kidneys with a
longer half-life and the other, blood, heart and liver with
a shorter half-life. The ANOVA test showed a significant
difference (confidence interval >95%) for the comparison
of heart with kidneys while the other comparisons of the
two groups showed a tendency towards a difference (con-
fidence interval <95%). Spleen half-lives appeared variable
compared with the half-lives of the other tissues, blood and
WB. This variability might have been due to differential
expression of CD20 on target cells.
Data shown in Table 2 were resolved for the half-lives
after the three individual injections per patient (Table 3) and
comparatively analysed for statistical differences between
injections and between patients, respectively. Since the T1/2α
would only marginally influence blood activity beyond 2
days after injection, a single exponential decrease was as-
sumed to occur between the blood samples of day 2, 3 or
4 and day 6 or 7, and an approximate T1/2β could be de-
termined for the individual injections. The results showed
only minor variations (mean CV=7.8%) in individual pa-
tients (Table 3).
The analysis of individual injections per patient showed
that the overall mean T1/2 values were very similar after the
three injections (Table 3). ANOVA showed the absence of
any significant difference between the three injections, with
the 95% confidence intervals ranging from 76 to 89, 74 to
91 and 75 to 86 h, respectively, for injections 1, 2 and 3, far
from any tendency towards significance (p>0.8).
When analysing the same data on a per patient basis, the
half-lives after the second and/or third injection compared
with the first one showed some marginal decreases in pa-
tients 3 and 4 and slight increases in patients 1 and 2. How-
ever, these variationswere rather random andnot significant,
with p>0.4 for the four analyses. Finally, an analysis of the
half-life data from blood and heart did not show any sig-
nificant difference either (p>0.6). Overall, also on a per pa-
tient basis or for blood and heart, no significant increase or
decrease in half-lives was observed in regard to the data of
Table 3.
In contrast, when the same results were sorted in a pa-
tient to patient comparison (n=18 for each patient), the
mean half-lives of patients 1 and 3 (T1/2=93.2±18.7 h and
85.7±14.6 h, respectively) appeared longer compared with
those of patients 2 and 4 (T1/2=71.9±9.0 h and 76.7±15.7 h,
respectively). ANOVA followed by the Tukey test con-
firmed that the half-lives of patient 1 were significantly
longer than those of patients 2 and 4 (confidence interval
>99%). For patient 3, the half-lives were significantly
longer than those of patient 2 (confidence interval >95%),
while the comparison of patients 3 and 4 showed only a
tendency towards a difference (confidence interval <95%).
Additional scans had been performed in three patients
at 2 and 4 weeks after the first and second injections, re-
spectively. The results suggested that a minor fraction of
radioactivity might have a longer half-life than the one
extrapolated from the first 7 days since in two of the three






















Fig. 4. Relative blood time-activity curves are shown, normalised to
initial activity. Mean effective T1/2α and β for each patient were
determined by fitting the 12 measurements from the three injections
per patient to bi-exponential curves
Table 3. Effective half-lives for individual organs and tissues as
calculated for individual injections. Blood effective T1/2β was esti-
mated from samples obtained 2–7 days post injection, as explained
Organ/tissue Patient Injection I Injection II Injection III
Liver 1 78.8 88.9 87.7
2 61.9 71.7 66.0
3 77.0 75.3 70.7
4 79.6 68.0 76.2
Heart 1 95.0 77.0 83.5
2 59.8 68.0 56.3
3 80.6 66.6 70.0
4 51.3 60.8 60.3
Spleen 1 100.5 121.6 90.0
2 72.9 70.0 72.2
3 92.4 100.5 87.7
4 79.7 65.4 71.5
Kidneys 1 84.3 150.7 86.6
2 81.5 81.5 87.7
3 115.5 101.9 93.7
4 100.5 77.9 108.3
Blood 1 80.3 66.9 88.9
2 62.8 71.0 67.3
3 69.5 73.4 75.1
4 73.0 64.9 64.5
WB 1 101.9 95.0 100.5
2 77.9 85.6 80.6
3 106.6 88.9 96.3
4 99.0 84.5 95.0
Mean±1 SD 82.6±16.1* 82.3±20.6* 80.7±13.5*
*The ANOVA did not indicate any significant difference between the
three injections, with p>0.8 for these overall comparisons. When
analysed on an individual patient basis, the fluctuations also
remained random, with p>0.4 for the four patients
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was slightly higher than the activity expected from themean
half-life calculated from the first week (Table 4).
Dosimetry and HAMA
Dosimetry was performed using Mirdose3.1 based on the
WB and tissue results determined from all scintigraphic
studies and using blood activity for determination of the
bone marrow dose. The mean effective radiation dose for
the four patients was calculated as 0.53±0.05 mSv/MBq
(range 0.48–0.59 mSv/MBq), the highest radiation dose
being delivered to the spleen followed in decreasing order
by kidneys, heart and liver (Table 5).
Absence of HAMA was verified in plasma samples
obtained before the study (as an inclusion criterion) and at 3
and 6 months post treatment initiation. All patients were
HAMA negative before entering the study and remained
negative 3 and 6 months after the study.
Discussion
The evolution of the biodistribution and tissue kinetics of
radiolabelled antibodies in individual patients undergoing
RITof lymphoma in combination with unlabelled antibody
treatment is an important parameter when considering re-
peated treatments. Furthermore, dosimetry estimates based
on diagnostic imaging performed 1–2 weeks before RITare
only reliable if the tissue distribution and biokinetics of
radiolabelled antibody do not change between the dosim-
etry study and RIT. It is generally assumed that these pa-
rameters remain constant in separate dosimetry and therapy
phases. However, to our knowledge, only a few graphical
presentations of blood activity measurements of 111In-
Zevalin compared with 90Y-Zevalin have been presented
[1] in support of this assumption.
In contrast to the aforementioned assumption, it has been
reported that the blood half-life of rituximab increases pro-
gressively after successive injections in standard Mabthera
treatment. The reported plasma half-life of rituximab in-
creased from a mean of only 33 h after the first injection to
77 h after the fourth injection in one group of patients [15],
and in another group it rose from an initial mean of 76±31 h
to 206±95 h at the fourth injection [14]. A further report
mentioned an average blood half-life of 226 h (range 13–
371 h) in a selected group of patients [23].
An obvious possible explanation for the reported pro-
longation of the blood half-life after successive unlabelled
antibody injections is that accessible antigen on normal B
cells and tumour either is progressively saturated or dis-
appears as cells die off. If this were the only explanation for
increasing circulation times of unlabelled antibodies, a
similar increase in blood and tissue half-lives would be
expected to occur for simultaneously injected 131I- or 90Y-
labelled antibodies. Such an increase in the biological half-
life of radiolabelled rituximab would invalidate dosimetry
measurements performed before RIT and would be a
particular handicap when envisaging repeated RIT.
In the four patients studied here, in the framework of
standard, unlabelled Mabthera treatment of lymphoma,
the measured biodistribution and pharmacokinetics of re-
peated 131I-labelled antibody injections remained constant
in blood, plasma and heart, and in all measured tissues and
total body, without any significant increase from the first to
the second or third injection.
WB radioactivity measurements showed a single ex-
ponential decrease, with an average T1/2 of 92.0±7.7 h for
the 12 injections. This is longer than the reportedmean half-
life of 59.3 h (range 24.6–88.6 h) observed for 131I-tosi-
tumomab [4], which is a very effective treatment [24]. Very
similar, overlapping WB half-lives of 3.2–7.5 days were
reported recently for another chimeric 131I-labelled anti-
body, G250 [25].
From the observed effective half-lives in blood, we cal-
culated an average biological T1/2β of 113 h (range 97.4–
142.8 h) for 131I-rituximab. This blood kinetic is again
similar to that reported for the 131I-labelled chimeric Mab
G250 [25]. As expected, this is markedly longer than the
biological half-life of 48 h (range 18–77 h) reported for
Table 5. Mean tissue radiation doses (mGy/MBq) and the effective
dose (mSv/MBq) are shown as calculated using Mirdose3.1 [20]
from attenuation-corrected tissue distributions
Patient Mean±1 SD
1 2 3 4
Liver 1.21 0.81 0.83 0.59 0.86±0.26
Kidneys 2.50 1.66 1.95 2.13 2.06±0.35
Spleen 2.26 1.65 1.69 3.41 2.25±0.82
Heart 1.46 1.27 1.42 1.88 1.51±0.26
Bone marrow 0.75 0.51 0.54 0.50 0.58±0.12
Total body 0.45 0.33 0.44 0.31 0.38±0.07
Effective dose
(mSv/MBq)
0.50 0.53 0.59 0.48 0.53±0.05
Bone marrow radiation dose was calculated from blood activity
measurements as proposed previously [21]
Table 4. Late WB activities (2 and 4 weeks after injection, re-
spectively) of patients 1, 2 and 3 are shown in percent of injected
activity (% ID), once as expected from the extrapolation of WB T1/2
calculated from the results of the first 7 days post injection and once
as observed values
Patient 1st injection, values at
2 weeks
2nd injection, values at
4 weeks
Extrapolated Observed Extrapolated Observed
1 12.0 15.7 0.95 2.0
2 6.1 7.5 0.35 1.1
3 9.6 9.4 0.86 1.2
Note that in patients 1 and 2, the observed activities at 2 or 4 weeks
post injection are slightly higher than the expected activities, while
the results are concordant in patient 3
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111In-Zevalin [1]. 111In-Zevalin is the radiolabelled mouse
MAb 2B8, parental to the chimeric rituximab C2B8. Blood
and plasma biological T1/2β values in our study are also
longer than the reported initial half-lives after the first
infusion of unlabelled rituximab [14, 23], and yet we started
our dosimetry phase in two patients with the first injection
of unlabelled rituximab. The WB results presented here
match well with reports of dosimetry studies of two other
groups [10, 11], who reported average effective WB half-
lives of 81 h (range 40–133 h) and 85.4 h (range 46–115 h),
respectively, for 131I-rituximab labelled with specific activ-
ities between 27 and 74 MBq/mg antibody.
The observed stability of radiolabelled rituximab in
terms of blood T1/2β and tissue half-lives in the course of
the unlabelled rituximab treatment remains puzzling. Since
radiolabelled rituximab represents only a small fraction of
unlabelled rituximab in this biodistribution setting, as is
also the case in RIT, one would expect the radiolabelled
antibody in blood and tissues to behave similarly to the
unlabelled antibody. This seems not to be the case, how-
ever. Different hypotheses may be suggested to explain
the apparent discrepancy between our results with radiola-
belled rituximab and those reported in the literature con-
cerning unlabelled rituximab [14, 15]. It is to be mentioned
that in standard rituximab treatment, an intentional rise in
blood antibody titres is achieved by the weekly injections of
unlabelled antibody, with the aim of prolonging therapeutic
titres. Thus, at the time of the fourth injection, an important
residual proportion of blood antibody from the third and
second injections is already in the T1/2β phase, or possibly
even in a third phase. The increase in the blood half-life of
unlabelled rituximab could thus be partially explained by
this cumulative effect.
In contrast to the observations with unlabelled rituximab
[14, 15], in our study only minor amounts of radiolabelled
antibody remained at the second and third injections from
the respective previous injections. In fact, at the second
131I-rituximab injection the fraction remaining from the
first injection (after a 2-week interval) was less than 15%,
while at the third injection (after a 4-week interval) remain-
ing activity was less than 2% (these fractions were de-
termined in three of our four patients). Thus, in contrast to
the measurements with unlabelled antibody, our biokinetic
study of radiolabelled antibody essentially analysed the
behaviour of freshly injected activity.
A second relevant observation concerns the fact that
tissue and blood/plasma kinetics of 131I-rituximab were
measured directly by radioactivity counting and WB scin-
tigraphy, while the blood fractions of unlabelled antibody
[14, 15] were determined immunologically. It is possible
that the half-life of 131I-rituximab may have been shortened
slightly by some dehalogenation, whereby unlabelled anti-
body would be generated. A further shortening of the half-
life of radiolabelled antibodies may have occurred due to
some degradation in the reticuloendothelial system (RES).
We recently calculated that with a labelling of 185MBq 131I
per mg antibody, such as was used here, 0.87 iodine atoms
were introduced per antibody molecule [16]. Despite this
low specific activity, a majority of radiolabelled antibodies
were in fact calculated to contain two or more iodine atoms
per antibody molecule [16]. This may have contributed
to some clearing of radiolabelled antibodies in the RES.
However, it is to be mentioned that none of the radiola-
belled antibody fractions that were controlled by HPLC
showed any damage that could be attributed to the radio-
labelling procedure. Furthermore, the half-lives observed
here are rather long, and dehalogenation or RES degrada-
tion, if either occurred, would have been of marginal rel-
evance. Finally, the half-lives observed in this study are
similar to those reported in two other studies using 131I-
rituximab labelled at specific activities between 27 and
74 MBq per mg antibody [10, 11].
It could be argued that a biokinetic study using weekly
injections of radiolabelled antibody might have given a
different result owing to the cumulation of larger fractions
of radiolabelled antibody remaining from preceding in-
jections. While this is possibly true, such measurement was
not the aim of this study. Instead, we considered that the
difference of activity in the dosimetry and therapy phases
with 131I-labelled rituximab is generally more than tenfold.
Even after a short 7-day interval, the biokinetics of the
therapeutic activity would be onlymarginally influenced by
the low activity remaining from the dosimetry phase. Thus,
separation of the repeated injections of 131I-rituximab in our
study was justified by its usefulness for interpretation of
RIT dosimetry and for the intended repetition of RIT, where
injections are separated by more than 2–3 weeks.
Furthermore, separation of injections by 2 or more weeks
should allow more reliable detection of small increases in
half-life than would be possible with an interval of 1 week
between injections. This is particularly true for our study,
since unlabelled antibody injections were continued week-
ly between the first and second injections of 131I-rituximab.
Finally, the half-life of unlabelled rituximab [14, 23] was
determined only after the first and fourth antibody injections.
Dosimetry was not a central aim of this study. However,
it is well recognised that among dosimetry parameters, the
blood-derived bone marrow dose underestimates the effec-
tive dose whenever CD20-expressing target cells, whether
normal or tumoural, are present in red marrow and radio-
labelled antibody is concentrated on these cells. While it
has been repeatedly reported that normal B cells rapidly
decrease in the blood after infusion of anti-CD20 antibody
in therapeutic amounts, the consequence of this decrease
for bone marrow accumulation of radiolabelled rituximab
has not yet been investigated.
Tumour radiation dose was not evaluated in this study.
Activity in regions containing tumour appeared to be sim-
ilar after the repeated injections in individual patients; how-
ever, assessment of tumour radiation dose requires particular
evaluations, notably volume determination in the case of
small tumours. It remains a matter of debate whether tu-
mour dose derived from sequential scintigraphic imaging
and efficacy are correlated in lymphoma [26]. Normal tis-
sue radiation dose, however, remains a matter of concern,
especially in high-dose RIT [27] and repeated RIT.
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Conclusion
The results of this study show that the blood, tissue andWB
biodistributions and kinetics of 131I-rituximab remain
constant in individual patients after successive injections
of radiolabelled antibody in combination with standard,
weekly injections of unlabelled antibody. The results thus
suggest that dosimetry studies are relevant for subsequent
therapies not only with respect to WB kinetics but also for
biodistribution and kinetics in tissues of concern, such as
kidneys or liver and possibly bone marrow. This study
might thus contribute to the understanding of the corre-
lation between pre-treatment assessment of normal tissue
radiation dose and delivered radiation dose in the subse-
quent RIT.
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